Glycemic variability evaluated by HbA1c rather than fasting plasma glucose is associated with adverse cardiovascular
Lijuan Sheng1, Guifang Yang2,3,4, Xiangping Chai2,3,4
1Clinical Nursing Teaching and Research Section, Second Xiangya Hospital, Central South University, Changsha, China.
Insights
Increased hemoglobin A1c (HbA1c) variability, not fasting plasma glucose (FPG) variability, is linked to major adverse cardiovascular events (MACEs) in type 2 diabetes. Intensive glucose control may worsen this association.
Area of Science:
- Cardiology
- Endocrinology
- Metabolic Diseases
Background:
- Glycemic variability is linked to cardiovascular disease risk.
- Few studies compare HbA1c and FPG variability concerning cardiovascular events in type 2 diabetes mellitus (T2DM).
Purpose of the Study:
- To investigate the association between HbA1c and FPG variability and major adverse cardiovascular events (MACEs) in T2DM patients.
- To explore the impact of glucose control strategies on this relationship.
Main Methods:
- Post hoc analysis of the ACCORD study.
- Cox proportional hazards models used to assess HbA1c/FPG variability and MACEs incidence.
- Analysis included 9,547 T2DM patients with a median follow-up of 4.6 years.
Main Results:
- Higher HbA1c variability quartiles showed a significant increase in MACEs risk (HR 1.37 in the fourth quartile).
- FPG variability was not significantly associated with MACEs (P for trend=0.28).
- A U-shaped relationship observed between glycemic variability and MACEs; intensive glucose control amplified MACEs risk with higher HbA1c variability (P for interaction <0.01).
Conclusions:
- In T2DM, increased HbA1c variability, not FPG variability, is significantly associated with MACEs.
- Glycemic variability exhibits a U-shaped relationship with MACEs.
- Glucose control strategy influences the HbA1c variability-MACEs link, with intensive control posing higher risk.
Background:
Although studies have shown that glycemic variability is positively associated with an increased risk of cardiovascular disease, few studies have compared hemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) variability with adverse cardiovascular events in patients with type 2 diabetes mellitus (T2DM).
Methods:
This was a post hoc analysis of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study. Cox proportional hazards models were used to explore the relationship between HbA1c or FPG variability and the incidence of major adverse cardiovascular events (MACEs).
Results:
In total, 9,547 patients with T2DM were enrolled in this study. During the median 4.6 ± 1.5 years follow-up period, 907 patients developed MACEs. The risk of MACEs increased in the HbA1c variability group in each higher quartile of HbA1c variability (P < 0.01). Compared with those in the first quartile of HbA1c variability, patients in the fourth quartile had a hazard ratio of 1.37 (Model 2, 95% confidence interval: 1.13-1.67) for MACEs. Higher FPG variability was not associated with a higher risk of MACEs in patients with T2DM (P for trend=0.28). A U-shaped relationship was observed between HbA1c and FPG variability, and MACEs. Glucose control therapy modified the relationship between HbA1c and MACEs; participants with higher HbA1c variability receiving intensive glucose control were more likely to develop MACEs (P for interaction <0.01).
Conclusion:
In adults with T2DM, the relationship between glycemic variability evaluated using HbA1c and FPG was U-shaped, and an increase in HbA1c variability rather than FPG variability was significantly associated with MACEs. The relationship between HbA1c variability and MACEs was affected by the glucose control strategy, and a higher HbA1c variability was more strongly associated with MACEs in patients receiving an intensive glucose control strategy.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Hypoglycemia and Glucagon
Diabetes: Symptoms, Diagnosis, and Complications
Overview of Carbohydrate Metabolism
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Variability: Analysis
The range is a simple measure of variability, indicating the difference between the highest and...


